Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of 3BNC117-LS-J and 10-1074-LS-J in Healthy Adults
NCT04173819Phase 2Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Feb 2020
- Primary completion
- Sep 2023
- Modality
- Anti-infectious Disease mAbs
- Countries
- 5
01
Overview
Phase 2, randomised trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (10 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Adverse Events at 92 Weeks, Serious Adverse Events at 92 Weeks and 2 more. Started Feb 2020; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04173819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173819.